Viatris News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

06.08.23	Ausblick: Viatris informiert über die jüngsten Quartalsergebnisse (finanzen.net)
31.07.23	Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstr... (PR Newswire)
23.07.23	Erste Schätzungen: Viatris legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
07.07.23	ROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS (PR Newswire)
01.07.23	ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS (PR Newswire)
28.06.23	Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023 (PR Newswire)
20.06.23	ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
14.06.23	ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
08.06.23	ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
01.06.23	VTRS INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
30.05.23	Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023 (PR Newswire)
25.05.23	ROSEN, A RESPECTED AND LEADING FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
22.05.23	Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year (PR Newswire)
22.05.23	Viatris Announces Appointment of Leo Groothuis to Company's Board of Directors (PR Newswire)
18.05.23	ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
17.05.23	Viatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
16.05.23	Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine (PR Newswire)
08.05.23	Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update (RTTNews)
08.05.23	Viatris Inc. Q1 Income Falls (RTTNews)
08.05.23	Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] (PR Newswire)
24.04.23	Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting (PR Newswire)
23.04.23	Erste Schätzungen: Viatris präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
12.04.23	Viatris to Report First Quarter 2023 Financial Results on May 8, 2023 (PR Newswire)
06.04.23	NCD Academy Launches New Health Equity and Social Determinants of Health Course (PR Newswire)
31.03.23	Viatris Wins Summary Judgment in New York Securities Class Action (PR Newswire)
27.02.23	Viatris Names Scott Smith CEO, Succeeding Michael Goettler, With Effect From April 1 (RTTNews)
27.02.23	Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023 (PR Newswire)
27.02.23	Viatris Sees Weak Revenues, Adj. EBITDA In FY23 - Update (RTTNews)
27.02.23	Viatris Inc. Q4 Earnings Summary (RTTNews)
27.02.23	Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance (PR Newswire)
26.02.23	Ausblick: Viatris legt Quartalsergebnis vor (finanzen.net)
15.02.23	Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (PR Newswire)
03.01.23	Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division (PR Newswire)
29.12.22	Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors (PR Newswire)
23.12.22	Viatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
14.12.22	Viatris Announces Donations Totaling $1 Million to Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship (PR Newswire)
14.12.22	Viatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi) (PR Newswire)
13.12.22	Calliditas To Work With Viatris To Bring Nefecon To Japanese Patients (RTTNews)
13.12.22	Shield Therapeutics To Work With Viatris To Bring Accrufer In The U.S. (RTTNews)
29.11.22	Viatris Completes Biosimilars Transaction with Biocon Biologics (PR Newswire)
18.11.22	Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences (PR Newswire)
10.11.22	Viatris, Kindeva Announce U.S. Court's Invalidation Of AstraZeneca's Symbicort Patent (RTTNews)
10.11.22	Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent (PR Newswire)
07.11.22	Viatris To Acquire Oyster Point And Famy Life Sciences To Create Ophthalmology Franchise (RTTNews)
07.11.22	Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event (PR Newswire)
07.11.22	Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update (RTTNews)
07.11.22	Viatris Inc. Profit Climbs In Q3 (RTTNews)
07.11.22	Viatris Reports Strong Third Quarter 2022 Results (PR Newswire)
06.11.22	Ausblick: Viatris mit Zahlen zum abgelaufenen Quartal (finanzen.net)
24.10.22	Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

18.03.25		Handel in New York: S&P 500 zum Ende des Dienstagshandels leichter
18.03.25		Angespannte Stimmung in New York: S&P 500 präsentiert sich am Nachmittag schwächer
18.03.25		Angespannte Stimmung in New York: S&P 500 fällt mittags zurück
03.03.25		Montagshandel in New York: S&P 500 verliert nachmittags
03.03.25		S&P 500-Handel aktuell: So steht der S&P 500 aktuell
27.02.25		Anleger in New York halten sich zurück: S&P 500 verbucht zum Handelsende Verluste
27.02.25		S&P 500 aktuell: S&P 500 verliert nachmittags
27.02.25		Schwache Performance in New York: So performt der S&P 500 am Donnerstagmittag

18.03.25

Handel in New York: S&P 500 zum Ende des Dienstagshandels leichter

18.03.25

Angespannte Stimmung in New York: S&P 500 präsentiert sich am Nachmittag schwächer

18.03.25

Angespannte Stimmung in New York: S&P 500 fällt mittags zurück

03.03.25

Montagshandel in New York: S&P 500 verliert nachmittags

03.03.25

S&P 500-Handel aktuell: So steht der S&P 500 aktuell

27.02.25

Anleger in New York halten sich zurück: S&P 500 verbucht zum Handelsende Verluste